Nambi V - Search Results

1

Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study.

Lewis AA, Ayers CR, Selvin E, Neeland I, Ballantyne CM, Nambi V, Pandey A, Powell-Wiley TM, Drazner MH, Carnethon MR, Berry JD, Seliger SL, DeFilippi CR, de Lemos JA. Lewis AA, et al. Among authors: nambi v. Circulation. 2020 Mar 24;141(12):957-967. doi: 10.1161/CIRCULATIONAHA.119.043628. Epub 2020 Jan 14. Circulation. 2020. PMID: 31931608 Free PMC article.

2

ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients.

Nambi V, Ballantyne CM. Nambi V, et al. Curr Atheroscler Rep. 2004 Sep;6(5):353-8. doi: 10.1007/s11883-004-0046-1. Curr Atheroscler Rep. 2004. PMID: 15296701 Review.

3

Apolipoprotein A-I and high-density lipoprotein: is this the beginning of the era of noninvasive angioplasty?

Ballantyne CM, Nambi V. Ballantyne CM, et al. Among authors: nambi v. J Am Coll Cardiol. 2004 Oct 6;44(7):1436-8. doi: 10.1016/j.jacc.2004.07.018. J Am Coll Cardiol. 2004. PMID: 15464324 Free article. Review. No abstract available.

4

Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk.

Nambi V, Ballantyne CM. Nambi V, et al. Curr Atheroscler Rep. 2005 Feb;7(1):22-8. doi: 10.1007/s11883-005-0071-8. Curr Atheroscler Rep. 2005. PMID: 15683598 Review.

5

Markers of inflammation and their clinical significance.

Ballantyne CM, Nambi V. Ballantyne CM, et al. Among authors: nambi v. Atheroscler Suppl. 2005 May;6(2):21-9. doi: 10.1016/j.atherosclerosissup.2005.02.005. Atheroscler Suppl. 2005. PMID: 15823493 Review.

6

Fat, fit, and leading the charge: the evolution of measuring high-density lipoprotein subpopulations.

Nambi V, Ballantyne CM. Nambi V, et al. Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2013-5. doi: 10.1161/01.ATV.0000186043.86570.4f. Arterioscler Thromb Vasc Biol. 2005. PMID: 16199755 No abstract available.

7

Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events.

Nambi V, Ballantyne CM. Nambi V, et al. Curr Atheroscler Rep. 2006 Sep;8(5):374-81. doi: 10.1007/s11883-006-0034-8. Curr Atheroscler Rep. 2006. PMID: 16901407 Review.

8

Combination therapy with statins and omega-3 fatty acids.

Nambi V, Ballantyne CM. Nambi V, et al. Am J Cardiol. 2006 Aug 21;98(4A):34i-38i. doi: 10.1016/j.amjcard.2005.12.025. Epub 2006 May 30. Am J Cardiol. 2006. PMID: 16919515 Review.

9

Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management.

Lumsden AB, Rice TW, Chen C, Zhou W, Lin PH, Bray P, Morrisett J, Nambi V, Ballantyne C. Lumsden AB, et al. Among authors: nambi v. World J Surg. 2007 Apr;31(4):695-704. doi: 10.1007/s00268-006-0732-y. World J Surg. 2007. PMID: 17345122 Review.

10

Role of biomarkers in developing new therapies for vascular disease.

Nambi V, Ballantyne CM. Nambi V, et al. World J Surg. 2007 Apr;31(4):676-81. doi: 10.1007/s00268-006-0712-2. World J Surg. 2007. PMID: 17387551 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

312 results

Search Page

Filters